• Intranet
    DARE-NL
    • About
      • DARE-NL
      • What are ATMPs (ENG)
      • More information
      • Wat zijn ATMPs (NL)
      • Meer weten?
    • Activities
      • Workpackage 1
      • Workpackage 2
      • Workpackage 3
      • Workpackage 4
      • Workpackage 5
      • Workpackage 6
      • Workpackage 7
    • People and Partners
      • Organisation
      • Supporting organisations
      • Management Team
      • Project Team
      • Steering Committee
      • Patient Advisory Board
      • Patient Participation Review Committee
      • Scientific Advisory Board
      • Vacancies
    • Courses & Events
      • Course directory
      • Submit new course
      • External course directories
      • Educational Programs
      • Upcoming events
      • Past events
      • Annual meeting
        • Annual meeting 2025
          • Program
          • Sponsors
          • Pictures
        • Annual Consortium Meeting 2024
        • Annual Consortium Meeting 2023
    • Resources
      • Tools
        • ATMP & Regenerative medicine
        • Regulations
        • Costs and lead times
        • Clinical trials
      • Publications
        • All publications
        • News items
        • Scientific articles
      • Newsletters
      • Links
    • Get in touch
    • Click to open the search input field Click to open the search input field Search
    • Menu Menu

    ZonMW/PharmaNL funding awarded

    News items, News_homepage, Uncategorized
    https://www.dare-nl.nl/wp-content/uploads/2026/02/Pharma-NL-kick-vierkant.jpg 2400 2400 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2026-02-09 16:48:522026-02-09 16:48:52ZonMW/PharmaNL funding awarded

    Advancing ATMPs for orphan diseases: redefining the roles of pharmaceutical companies and academia

    Scientific articles, Uncategorized
    https://www.dare-nl.nl/wp-content/uploads/2026/02/picture-scientific.png 112 670 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2026-02-09 13:49:352026-02-10 14:05:20Advancing ATMPs for orphan diseases: redefining the roles of pharmaceutical companies and academia

    Project Manager DARE-NL

    Uncategorized
    https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png 0 0 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2026-01-19 11:46:312026-01-19 11:46:31Project Manager DARE-NL

    DARE-NL organizes ATMP Trial Registry Symposium

    Uncategorized
    21 August, 2025
    https://www.dare-nl.nl/wp-content/uploads/2025/08/DSC2694.jpg 2400 2400 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2025-08-21 12:06:282026-02-09 16:49:48DARE-NL organizes ATMP Trial Registry Symposium

    MHRA issues new regulation on modular and POC manufacture of ATMPs

    Uncategorized
    21 August, 2025
    https://www.dare-nl.nl/wp-content/uploads/2025/04/UK-MHRA.jpg 249 374 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2025-03-11 12:00:232025-08-22 07:58:18MHRA issues new regulation on modular and POC manufacture of ATMPs

    DARE-NL Workshop: Regulatory Sciences, HTA & ATMP-NL

    Uncategorized
    21 August, 2025
    https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png 0 0 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2025-02-03 12:36:102025-03-21 13:29:46DARE-NL Workshop: Regulatory Sciences, HTA & ATMP-NL

    ATMP operator workshop

    Uncategorized
    3 February, 2025
    https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png 0 0 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2025-02-03 10:58:322025-03-31 10:26:48ATMP operator workshop

    CTGCT webinar by UCL experts: Introduction to IP and commercialisation

    Uncategorized
    3 February, 2025
    https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png 0 0 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2025-01-24 11:59:132025-01-24 11:59:35CTGCT webinar by UCL experts: Introduction to IP and commercialisation

    Annual consortium meeting

    Uncategorized
    27 September, 2024
    https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png 0 0 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-09-27 12:37:202025-03-12 15:49:51Annual consortium meeting

    Is the proposed EU General Pharmaceutical Legislation ready to support pharmaceutical innovation?

    News items, Uncategorized
    27 September, 2024
    https://www.dare-nl.nl/wp-content/uploads/2024/07/VWS-rapport-3.jpg 766 799 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-04-30 12:00:482024-08-28 12:10:29Is the proposed EU General Pharmaceutical Legislation ready to support pharmaceutical innovation?
    Page 1 of 212

    Contact us at info@dare-nl.nl

    Scroll to top Scroll to top Scroll to top
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}